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NPAG programme for ka, kel and Vd indicating that the 
model was stable by the time convergence was achieved 
after 500 cycles. 
Predicted versus observed concentrations found with the 
NPAG programme using Bayesian prediction showing a 
good fit for the model (~ = 0.96). 
Three-dimensional plot of Vd versus kel for NPAG 
showing a cluster of main population and the possible 
presence of two subpopulations having lower (A) and 
higher kel (B) values respectively. 
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Population Pharmacokinetics of Repaglinide in Healthy Subjects and Genetic 
Polymorphisms of CYP3A4 and CYP2CB 
ABSTRACT 
Repaglinide is a novel prandial glucose regulator (PGR) for the treatment of 
type 2 diabetes mellitus. Repaglinide is mainly metabolised in the liver by CYP3A4 
and CYP2C8 enzymes. The objective of the present study is to investigate the 
effects of the CYP3A4 and CYP2C8 genotypes on the pharmacokinetics of 
repaglinide in 121 healthy Malaysian subjects. 
The study protocol was approved by our local Research and Ethics 
Committee, School of Medical Sciences, Universiti Sains Malaysia. Initially, a new 
HPLC method using a simple liquid-liquid extraction for the determination of 
repaglinide in human serum was developed and later validated. Then, PCR 
methods were optimized to detect CYP3A4 and CYP2C8 genetic polymorphisms 
among healthy Malaysian subjects. 
Each subject received 4 mg of oral repaglinide. Six blood samples per 
individual were taken (0 min, 30 min, 60 min, 120 min, 180 min and 240 min) for 
repaglinide's serum concentration determination by using HPLC. NPAG was then 
used to determine population pharmacokinetic parameter values of repaglinide. 
The developed HPLC method was selective and calibration curves of 
repaglinide were found to be linear in the concentration range of 20-200 ng/ml. The 
limits of detection (LOD) and quantification (LOQ) were 10 ng/ml and 20 ng/ml, 
respectively. The inter-day precision was from 5.21% to 11.84% while the intra-day 
precision ranged from 3.90% to 6.67%. The inter-day accuracy ranged between 
XX 
89.95% and 105.75% with the intra-day accuracy ranging from 92.37% to 
104.66%. No mutations were detected for the CYP3A4*4 and CYP3A4*5 alleles. 
The allele frequency of the CYP3A4*18 allele was 2.07%. All five subjects with 
CYP3A4*18 mutations were found to be heterozygous. For CYP2C8, the allele 
frequency for both CYP2C8*2 and *3 was 0.4% while the allele frequency for 
CYP2C8*5 was 4.13%. All subjects with mutations were found to be heterozygous. 
No mutation was detected for the CYP2C8*4 allele. CYP2C8 and CYP3A4 
genotypes were not significantly associated with changes in the blood glucose 
lowering effect of repaglinide. On the other hand, the CYP3A4 genotype 
significantly influenced repaglinide's pharmacokinetics where the mean elimination 
rate constant (kel) was 34% lower (p = 0.04) and the mean half-life (t112) was 133% 
longer (p = 0.04) in subjects having the CYP3A4*11*18 genotype compared to 
those having the CYP3A4*11*1 genotype. 
In conclusion, CYP3A4 activity plays an important role in influencing 
repaglinide's pharmacokinetics. 
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Farmakokinetik Populasi Repaglinide di dalam Subjek Sihat dan Folimorfik 
Genetik CYP3A4 dan CYP2CB 
ABSTRAK 
Repaglinide adalah sejenis ubat pengawal glukosa prandial untuk merawat 
penyakit kencing manis jenis 2. Repaglinide dimetaboliskan di dalam hepar oleh 
enzim CYP3A4 dan CYP2C8. Tujuan kajian ini adalah untuk menyelidik kesan 
kedua-dua genotip CYP3A4 dan CYP2C8 ke atas farmakokinetik repaglinide di 
dalam 121 subjek sihat. 
Kajian ini telah diluluskan oleh Jawatankuasa Etika, Pusat Pengajian Sains 
Perubatan, Universiti Sains Malaysia. Kaedah HPLC menggunakan pengekstrakan 
cecair-cecair untuk penganalisaan repaglinide di dalam serum dibangunkan dan 
disahkan. Kemudian, kaedah PCR diubahsuai untuk menentukan polimorfisma 
genetik CYP3A4 dan CYP2,C8 di dalam subjek Malaysia yang sihat. Setiap subjek 
menerima 4 mg repaglinide secara oral. Enam sampel darah diambil daripada 
setiap subjek (0 min, 30 min, 60 min, 180 min dan 240 min) untuk analisa HPLC 
repaglinide di dalam serum. 
Kaedah HPLC yang dibangunkan adalah selektif dan keluk kalibrasinya juga 
adalah linear bagi julat kepekatan repaglinide di antara 20 sehingga 200 ng/ml. 
Tahap pengesanan paling minimum ialah 10 ng/ml manakala tahap kuantitasi 
paling minimum ialah 20 ng/ml. Kejituan dalam sehari adalah di antara 5.21% 
hingga 11.84% manakala kejituan di antara hari mempunyai julat di antara 3.90% 
sehingga 6.67%. Manakala ketepatan dalam sehari berjulat di antara 89.95% dan 
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105.75% dan ketepatan di antara hari pula mempunyai julat di antara 92.37% 
sehingga 104.66%. 
Tiada mutasi ditemui untuk aiel CYP3A4*4 dan CYP3A4*5. Frekuensi aiel 
CYP3A4*18 di dalam populasi Malaysia ialah 2.07%. Kelima-lima subjek yang 
mempunyai mutasi CYP3A4*18 adalah heterozigot. Frekuensi aiel bagi CYP2C8*2 
dan *3 adalah masing-masing 0.4% dan frekuensi aiel bagi CYP2C8*5 ialah 
4.13%. Kesemua subjek yang mempunyai mutasi adalah heterozigot. Tiada mutasi 
ditemui untuk aiel CYP2C8*4. Genotip untuk CYP2C8 dan CYP3A4 tidak signifikan 
untuk perubahan di dalam kesan penurunan glukosa darah repaglinide. Manakala 
bagi genotip CYP3A4 terdapat perbezaan yang signifikan di dalam farmakokinetik 
repaglinide di mana purata kadar konstan eliminasi repaglinide (kel) adalah 34% 
lebih rendah (p = 0.04) dan jangka masa separuh hayat (t112) pula adalah 133% 
lebih panjang (p = 0.04) di dalam subjek yang mempunyai genotip CYP3A4*11*18 
berbanding subjek normal. 
Kesimpulannya, aktiviti CYP3A4 memainkan peranan yang penting dalam 
mempengaruhi farmakokinetik repaglinide. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Diabetes mellitus 
1.1.1 Classification of Diabetes mellitus 
Diabetes means high blood sugar (glucose) or hyperglycaemia due to 
absolute or relative lack of insulin or insulin resistance (Tattersall, 1986, Rang & 
Dale, 1993). According to Rang & Dale (1993), hyperglycaemia occurs because 
the liver and skeletal muscles cannot store glycogen and the tissues are unable to 
utilise glucose. 
It is the leading cause of kidney failure (DeFronzo, 1995) and blindness 
(Neely et a/.,1998). It is also a major risk factor for heart diseases and stroke 
(Mafauzy, 2006a, Pertussona eta/., 2008). In Malaysia, the First National Health 
and Morbidity Survey (NHMS 1) conducted in 1986 reported a prevalence of 
diabetes of 6.3% and in the Second National Health and Morbidity Survey (NHMS 
2) in 1996, the prevalence had risen to 8.2% (Zaini, 2000, Mafauzy, 2006b). In a 
study in Kelantan, the prevalence was reported to be higher at 10.5% (Mafauzy et 
a/., 1999) 
Basically, there are two types of diabetes, Type 1 and Type 2 (Tattersall, 
1986, Kilo & Williamson, 1987, Rang & Dale, 1993). Both have similar symptoms 
but their causes are different (Kilo & Williamson, 1987). 
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In Type 1 or juvenile onset diabetes, the insulin-producing 13-cells of 
pancreas (i.e the Islet of Langerhans) are destroyed and produce little or no insulin 
at all. This type of diabetes is most common in the young. It is also known as 
Insulin-Dependent Diabetes Mellitus (IDDM) since the only treatment is by injection 
of insulin because all of the 13-cells have been destroyed. 
Type 2 or maturity onset diabetes is also known as Non-Insulin-Dependent 
Diabetes Mellitus. It occurs mainly in people over the age of 35 and usually in 
those who are fat (Kilo & Williamson, 1987). Their 13-cells of pancreas can produce 
some insulin but it is insufficient. NIDDM can be treated either by reducing the 
body's need for insulin (by losing weight or eating Jess) and/or stimulating the 
pancreas with one of the many medications available today for example 
sulphonylurea in order to produce more insulin. They usually do not require insulin 
injection. 
The number of diabetic individuals will continue to increase worldwide. 
According to estimations of the World Health Organization (WHO), in 1995 there 
were more than 135 million adults suffering from diabetes worldwide (King et a/., 
1995). According to WHO, it is projected that the total number of individuals with 
diabetes will rise to about 300 million in 2025 (King eta/., 1995). 
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1.1.2 Oral antidiabetic drugs 
1.1.2.1 General aspects 
The first attempts to treat human diabetes by orally-active drugs were made 
between 1925 and 1930 from synthalines and their derivatives. However, only in 
1940's that carbutamide and tolbutamide were used for antihyperglycaemic activity 
(Loubatieres, 1969). These are the first sulphonamide derivatives. 
Currently, there are five groups of oral antidiabetics in clinical use 
1) Sulphonylureas 
2) Biguanides 
3) Alpha-glucosidase inhibitor 
4) Thiazolidinediones 
5) Meglitinides analogue 
1.1.2.2 Sulphonylureas 
Oral antidiabetic drugs of the sulphonylurea family have been successfully 
used for the treatment of type 2 diabetes mellitus for more than four decades 
(Wascher & Boes, 2003). Their popularity is based on their ease of administration, 
reliable effectiveness and lack of symptomatic side effects other than 
hypoglycaemia (Groop, 1992). They are still the most favourable treatment 
approach. Sulphonylurea is an oral antidiabetic drug that acts mainly by increasing 
endogenous insulin secretion. 
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Sulphonylureas stimulate insulin release from ~-cell of the pancreas via 
binding to a sulphonylurea receptor (SUR1), thus blocking KATP channel which then 
leads to ~-cell depolarization, influx of calcium into the cells and eventual release 
of insulin (Ashcroft & Gribble, 1999). All sulphonylureas lower blood glucose levels 
in normal and in many patients with NIDDM. The two most popular sulphonylureas 
used to date are glibenclamide and gliclazide (Levy, 1999). According to Berger 
(1985), sulphonylureas are safe and effective drug for long-term treatment of 
diabetes. 
1.1.2.3 Biguanides 
The only biguanide drug currently in use in many countries is metformin 
(Berger, 1991 ). 
Biguanides do not affect glycaemia in normal individuals, but they exert a 
reproducible hypoglycaemic effect in hyperglycaemic patients. They only give 
peripheral effects (i.e does not stimulate insulin release (Levy, 1999) but they 
increase muscle glucose uptake and metabolism and decrease hepatic glucose 
production (gluconeogenesis) (Schafer, 1979, Dunn & Peters, 1995, Levy, 1999). 
According to Dunn & Peters (1995), biguanide is not metabolised to a significant 
extent and is primarily excreted unaltered in the urine. Biguanides work 
synergistically with the sulphonylureas. 
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1.1.2.4 Alpha-glucosidase inhibitor 
The a-glucosidase inhibitor inhibits enzymes that break down 
polysaccharides and sucrose in the small intestine leading to a slow down of 
glucose absorption from the gut (Balfour & McTavish, 1993, Levy, 1999). The first 
of the a-glucosidase inhibitor in clinical use was acarbose (Creuzfeldt, 1988, 
Balfour & McTavish, 1993). It is eliminated through two ways. The first is via 
intestinal digestive enzymes cleavage and the second is via biotransformation of 
the intestinal bacteria. According to Balfour & McTavish (1993), only trace amounts 
of unaltered acarbose are absorbed from the gastrointestinal tract into the systemic 
circulation. 
Miglitol is a newer a-glucosidase inhibitor (Levy, 1999). It has a similar 
action as acarbose but it is almost completely absorbed from the gastrointestinal 
tract (GIT), so it has higher bioavailability. Miglitol is not metabolised and is 
excreted unaltered (Scott & Spencer, 2000). 
1.1.2.5 Thiozolidinedione (TZD) 
Thiozolidinedione (TZD) is peroxisome proliferator-activated receptor 
gamma (PPARy) activator which was introduced in 1997. Rosiglitazone, 
traglitazone and pioglitazone are three examples of a TZD. They enhance the 
effects of insulin on cellular glucose and lipid metabolism. They are extensively 
metabolised in the liver (Mudaliar & Henry, 2001 ). 
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1.1.2.6 Meglitinide analogues 
Meglitinides have a mechanism of action similar to that of the 
sulphonylureas, but are more rapidly absorbed and eliminated (Biickie, 2006). They 
are taken with meals and due to their shorter duration of action, pose a smaller risk 
for hypoglycaemia (Dornhorst, 2001 ). Therefore, compared with sulphonylureas, 
meglitinides have been shown to provide a better control of postprandial 
hyperglycaemia and better adverse effects profile with a more favourable safety 
profile, especially in patients with renal failure (Scheen, 2007). 
Repaglinide, a benzoic acid derivative, was the first member of the meglitinide 
class. It was introduced in 1998. Nateglinide is a derivative of the amino acid 
phenylalanine and was introduced to the market in 2001 (Levine & Burns, 2001). 
Repaglinide can be used as monotherapy or in combination with metformin 
(Moses, 1999) whereas nateglinide is authorised only in combination therapy with 
metformin (Biickie, 2006). Both are actively metabolised in the liver and are rapidly 
eliminated with repaglinide having a half-life (t112) of only 1 h compared to 1. 7 h for 
nateglinide (Culy & Jarvis, 2001, Mcleod, 2004). 
1.2 Repaglinide 
The long plasma half-lives and the long lasting effects of some sulphonylureas 
for example 4 h for glipizide and 16 h for gliclazide (Yang eta/., 2007) increase the 
risk of hypoglyceamia (Melander et a/., 1989, Hatorp et a/., 1999). This risk is 
greatest among elderly patients (Berger, 1985). In up to 20% of patients treated 
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for six months, mild hypoglycaemia develops (Jennings eta/., 1989). The incidence 
of severe hypoglycaemia is approximately 0.2 per 1000 patients per year (Berger, 
1985). Moreover, the use of sulphonylureas can cause weight gain (Natrass, 
2000). 
Therefore, the usage of new agents with shorter half-lives in order to reduce 
the risk of hypoglycaemia is highly recommended. The usage of a new agent, 
repaglinide which has a half-life of 1 h with less hypoglycaemic effects, especially 
in elderly subjects with type 2 diabetes were recommended by the American 
Diabetes Association and the European Type 2 Policy Group (Alberti & Gries, 
1998). 
1.2.1 Therapeutic uses 
Repaglinide is a novel prandial glucose regulator (PGR) for the treatment of 
type 2 diabetes mellitus (Marbury et a/., 2000, Hatorp, 2002). It reduces glucose 
concentrations in patients with type 2 diabetes mellitus (Natrass, 2000) and is used 
when diet, exercise and weight reduction have not been found to control blood 
glucose well enough on their own. It helps to control blood sugar by increasing the 
amount of insulin released by the pancreas. 
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1.2.2 Formulation, chemical properties and stability 
Repaglinide is a new carbomoxylmethyl benzoic acid derivative chemically 
known as 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl) phenyl] butyl] amino]-2-
oxoethyl] (Figure 1.1). It is an (S)(+)-enantiomer. 
Repaglinide is a white to off-white powder with shaped crystals. It is slightly 
soluble in aqueous acid, very soluble in aqueous phase and freely soluble in 
methanol and ethanol. 
It is called Prandin in the United States, NovoNorm in Europe and 
Gluconorm in Canada. 
1.2.3 Mechanism of action 
Repaglinide is a non-sulphonylurea oral hypoglycaemic agent that is rapidly 
absorbed. It stimulates pancreatic insulin secretion via the sulphonylurea receptor. 
According to Dornhorst (2001 ), this receptor is a subunit of the ATP-sensitive 
potassium channel (KATP channel). It produces a hypoglycaemic effect by 
stimulating insulin secretion from the pancreatic p-cell (Henquin eta/., 1987, Levy, 
1999). It initiates insulin secretion by closing the KATP channel (Dornhorst, 2001 ). 
When the sulphonylurea binds to the p-cell it leads to depolarisation of the p-cell 
with influx of calcium ions and secretion of insulin from its cell. 
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Figure 1.1 Chemical structure of repaglinide 
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1.2.4 Pharmacokinetics properties 
Previous clinical trials have shown that repaglinide is rapidly absorbed from 
the gastrointestinal tract after oral administration. The peak plasma concentration 
is reached 30-60 min after administration (Guay, 1998). After reaching the peak, 
plasma levels decrease rapidly and the drug is eliminated within 4 to 6 h. Its 
absolute bioavailability is 63% but its absorption is not affected by food. The half-
life of repaglinide is about 1 h (Hatorp eta/., 1998). Repaglinide has low volume of 
distribution (Vd) which is about 24.4 L at steady state (Hatorp, 2002). In human, it 
is highly bound (more than 98%) to plasma protein albumin. 
Repaglinide is mainly metabolised in the liver by an · oxidative 
biotransformation (Gaal eta/., 2001 ). Repaglinde is eliminated by metabolism to at 
least five different metabolites, as shown in vivo (van Heiningen et a/., 1999) and in 
vitro (Bidstrup eta/., 2003). Repaglinide is metabolised by formation of an aromatic 
amine (M1), opening of the piperadine ring to form a dicarboxylic acid (M2), 
hydroxylation of the piperadine ring (M4), de-ethylation (M5), formation of a tauride 
(M6), formation of an acylglucuronide (M7) and by N-oxidation (M12) (Bidstrup et 
a/., 2003). M1 is formed directly from repaglinide, or by oxidative N-dealkylation 
from M2. In vitro, repaglinide (MO) can also be metabolised to MO-OH (Bidstrup et 
a/., 2003) (Figure1.2). 
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Figure 1.2 In vitro biotransformation pathways of repaglinide (Bidstrup eta/., 
2003) 
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The most important enzymes participating in the biotransformation of 
repaglinide are cytochrome P450 3A4 or CYP3A4 and cytochrome P450 2C8 or 
CYP2C8 (Bidstrup eta/., 2003). 
In human, the main metabolites of repaglinide are (M2) (about 66% of the 
dose), an aromatic amine (M1) (about 4% of the dose) and M4, while other 
metabolites are produced only in small amounts. However, none of its metabolites 
contributes to its blood-glucose-lowering activity. 
In vitro, both CYP3A4 and CYP2C8 have been shown to catalyse the 
biotransformation of repaglinide to its major metabolites, with M1 and M2 mainly 
formed by CYP3A4 and M4 mainly by CYP2C8. In vitro, CYP3A4 and CYP2C8 
contribute similarly to the metabolism of therapeutic repaglinide concentrations, 
with no significant biotransformation by other CYP enzymes (Kajosaari et a/., 
2005a). 
Repaglinide is excreted primarily through the bile (98%) (Owens, 1999). 
Only a very small fraction (less than 8%) of the administered dose is excreted 
through the urine (van Heiningen eta/., 1999). In the faeces, the major metabolite 
was M2 (66% of administered dose) (van Heiningen eta/., 1999). 
According to Marbury eta/. (2000), because repaglinide is mostly eliminated 
by non-renal routes, it may be an appropriate treatment for elderly subjects with 
renal impairment. Impaired renal function may result in greatly reduced excretion, 
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thus leading to accumulation of drug and also increasing the risk of hypoglycaemia 
(Marbury et a!., 2000). If repaglinide is used in patients with severely-impaired 
renal function, dose adjustments may be necessary if indicated by blood glucose 
levels (Schumacher eta/., 2003). The pharmacokinetics of repaglinide are similar 
in both young and elderly healthy subjects (Hatorp et a/., 1999}. The 
pharmacokinetic parameters as obtained from studies done by Hatorp eta!. (1999} 
and Marbury et a!. (2000) following a 2 mg oral single-dose of repaglinide are 
shown in Table 1.1. 
1.2.5 Dosage and administration 
Repaglinide should be taken before main meals (preprandially). It is ideally 
consumed 10 to 15 min before meals. According to Natrass (2000), it can be taken 
up to 30 min before a meal. It affects around meal time glucose load which is 
important to the treatment of type 2 diabetes mellitus. If a meal is skipped, the dose 
should also be skipped. Thus, repaglinide offers a treatment which can be adjusted 
to suit each individual's lifestyle (Damsbo eta/., 1999). 
For na"ive patients (HbA 1 c < 8%}, 0.5 mg of the dose should be taken 
before each meal whereas for patients previously treated with oral hypoglycaemic 
agents, the recommended dose is 2 mg before each meal (Hatorp, 2002). The 
recommended maximum single dose is 4 mg. The total maximum single dose per 
day should not exceed 16 mg (Novo Nordisk, 1998}. 
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Table 1.1 Values for serum repaglinide pharmacokinetic variables following a 
2 mg oral dose (single-dose regimen) (Hatorp eta/., 1999, Marbury eta/., 2000). 
Parameters Value 
AUC (ng/ml per h) 69. 0 ± 78.0 
Cmax (ng/ml) 47.9 ± 32.0 
tmax (h) 0.8 ± 0.6 
t1/2 (h) 1.0 ± 0.2 
kel (L/h) 0.37 
Vd (L) at steady state 24.4 
Vd (L) at elimination phase 28.9 
CL (Lih) 33.0 
Data are means ± standard error except where indicated 
AUC - area under the serum concentration-time curve 
Cmax - peak serum concentration 
lmax - time to reach Cmax 
t112 - half-life 
ke,- elimination rate constant 
Vd - apparent volume of distribution 
CL - clearance 
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Range 
(min- max) 
12.0-302.0 
18.0 - 127.0 
0.5-2.5 
0.7-1.3 
0.18-0.60 
1.2.6 Drug interactions 
The effect of CYP inhibition and induction on the pharmacokinetics of 
repaglinide have been studied in several cross-over studies in healthy volunteers. 
The CYP3A4 inhibitors clarithromycin, itraconazole, and ketoconazole have all 
been shown to moderately increase repaglinide's plasma concentrations (Niemi et 
a/., 2001, Hatorp, eta/., 2003, Niemi eta/., 2003). Clarithromycin and itraconazole 
increase repaglinide's AUC by about 40% (Niemi eta/., 2001, Niemi eta/., 2003) 
and ketoconazole by 15% (Hatorp, et a!., 2003). Gemfibrozil, a CYP2C8 inhibitor, 
increases repaglinide's AUC by 8-fold, considerably prolonging and enhancing the 
blood glucose-lowering effect of repaglinide (Niemi eta/., 2003). Combination of 
gemfibrozil and itraconazole causes a nearly 20-fold increase in repaglinide's AUC, 
and further enhances repaglinide's blood glucose lowering effect (Niemi et a/., 
2003). In patients taking both gemfibrozil and repaglinide, serious hypoglycaemic 
events have been reported (Laine eta!., 2003). The CYP3A4 inducer rifampicin 
decreases repaglinide's plasma concentrations and similar effects are expected 
with other CYP3A4 inducers. In one study, when repaglinide was administered 12 
h after the last rifampicin pre-treatment dose, repaglinide's AUC was reduced by 
57% (Niemi et a/., 2000) whereas in another study when repaglinide was 
administered simultaneously with the last rifampicin dose, a 31% reduction of 
repaglinide's AUC was seen (Hatorp, et a/., 2003). Possible drug interactions 
between repaglinide and a CYP inhibitor cimetidine, CYP3A4 substrates 
ethinyloestradiol (also a CYP2C9 and CYP2C19 inhibitor) (Laine et a/., 2003), 
simvastatin and nifedipine, and drugs with narrow therapeutic indices (digoxin, 
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theophylline or warfarin) have also been investigated. However, no significant 
pharmacokinetic changes were observed (Hatorp, eta/., 2000). 
1.2. 7 Adverse effects 
Repaglinide is well tolerated when taken orally (Culy & Jarvis, 2001). A 
study done by Marshall et a/. (2006) in general practice in England reported that 
the most frequent adverse drug reactions were diarrhoea, followed by abdominal 
pain nausea and vomiting. Adverse events of hypoglycaemia are similar to those 
caused by sulphonylurea treatment with serious hypoglycaemic effects occurring 
more with sulphonylureas than repaglinide. 
1.2. 7 Contraindications 
Repaglinide is contraindicated in patients with hypersensitivity to the drug 
(Novo Nordisk, 1998). Patients who suffer from diabetic ketoacidosis should be 
treated with insulin and should not use repaglinide. The safety of repaglinide in 
pregnant women has not been established and therefore it is not recommended for 
use during pregnancy as the potential for low blood glucose in nursing infants may 
exist. This drug has not been studied in children and is therefore best avoided in 
this group of people. Patients with hepatic disorders should also not use this drug. 
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1.3 Pharmacokinetics, drug metabolism and pharmacogenetics 
1.3.1 Pharmacokinetics 
Measurement of drug concentrations in the blood, serum or plasma is the 
most direct approach of assessing· the pharmacokinetics of drugs in the body 
(Shargel & Yu, 1999). Sensitive, accurate, precise analytical methods are required 
for the direct measurement of drugs in biologic samples. Thus, in this study, high-
performance liquid chromatography (HPLC) was used for the determination of 
serum repaglinide's levels. 
1.3.2 Drug metabolism and CYP enzyme system 
All drugs are eliminated from the body by excretion and metabolism. Most 
drugs are lipid soluble compounds, which require biotransformation into more 
hydrophilic form before they can be excreted from the body (Sweeney & Bromilow, 
2006). Drugs are most often metabolised in the liver by enzymes localised in the 
endoplasmic reticulum of hepatocytes. Drug metabolism can also occur in other 
tissues, for example the gastrointestinal tract, lungs and kidneys. 
Drug metabolism can generally be divided into Phase I reactions (oxidation, 
reduction or hydrolysis) . and Phase II reactions (acetylation, glucuronidation, 
sulphation and methylation). Phase II may precede Phase I and occurs without 
prior oxidation, reduction or hydrolysis if there are polar compounds (Sweeney & 
Bromilow, 2006). Both, most often, convert relatively lipid soluble drugs into 
relatively more water soluble or hydrophilic metabolites. 
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The cytochrome P450 (CYP) system is the most important xenobiotic 
metabolising system. Approximately 80-90% of human drug metabolism is GYP-
mediated (Wong et at., 1991, Anzenbacher & Anzenbacherova, 2001). Most of the 
CYP-catalysed reactions lead to detoxification of xenobiotics. 
The CYP enzymes are a superfamily of heme-containing enzymes that are 
found on the endoplasmic reticulum. These isoenzymes are so called because· 
they have a spectrophotometric absorption peak at or near 450 nm when bound 
and reduced by carbon monoxide (Nebert & Gonzalez, 1987). The most important 
property of all known P450s is their ability to bind and activate two atoms of oxygen 
in a drug molecule (Anzenbacher & Anzenbacherova, 2001). The CYPs 
constituting a family should have 40% similar sequences in their overlapping 
portions while a subfamily is created based on higher degree (55%) of sequence 
similarity (Anzenbacher & Anzenbacherova, 2001 ). 
To date, a total of 57 CYP enzymes have been identified in humans 
(lngelman-Sundberg et a/., 2000). The families CYP1, CYP2, and CYP3 are 
primarily associated with the metabolism of exogenous compounds, whereas the 
other CYPs have mainly endogenous roles (lngelman-Sundberg eta/., 2000). 
The CYPs are found primarily in the liver and the gut mucosa and also can 
be found in the lungs, the kidney, the small intestines and brain in a small amount 
(Zagaria, 2004). In the liver, CYP3A4 is quantitatively the most important, with 
CYP2C8, CYP2C9, CYP2A6, CYP2E1 and CYP1A2 present in somewhat lower 
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quantities; CYP2C19 and CYP206 are of relatively minor quantitative importance, 
but their clinical importance is high (Shimada eta/., 1994). CYP3A4 is the major 
form of CYP expressed in enterocytes, and members of CYP2C subfamily are also 
significantly expressed (Zhang et a/., 1999). Table 1.2 lists some of the CYP 
enzymes responsible for metabolic transformation of drugs. 
1.3.3 Pharmacogenetics 
Drug levels in plasma may vary more than 1 000-fold between two 
individuals having the same weight and with the same drug dosage (lngelman-
Sundberg, 2001 ). This interindividual variation is caused by several factors which 
can be divided into physiological and environmental (McKinnon & Evans, 2000, 
Koo & Lee, 2006). Physiological factors include age, gender, ethinicity, genetic 
factors and body weight while environmental factors include nutritional status, 
concurrent drug therapy and exposure to certain chemicals. 
The term "polymorphism" is used to describe allelic variant that are detected 
in more than 1% of a given population (Roden, 2001 ). Genetic polymorphism is a 
common source of interindividual difference in drug metabolism (lnaba et a/., 
1995). Much of this variation has shown to be caused by genetic polymorphisms of 
the CYP enzymes (Nebert & Gonzalez, 1987). 
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Table 1.2 Some example of human P450 enzymes (Anzenbacher & 
Anzenbacherova, 2001). 
CYP 
CYP 1A1 
CYP 1A2 
CYP 181 
CYP 2A6 
CYP 281/2 
CYP 286 
CYP 2C8 
CYP 2C9/10 
CYP2C19 
CYP206 
CYP2E1 
CYP2F 
CYP3A4/5 
CYP3A7 
CYP4A9/11 
CYP481 
CYP4F2/3 
Localisation 
lung, liver, brain, GIT, lymphocytes, heart 
liver 
skin, brain, heart, lung, placenta, liver, kidney, 
GIT, spleen 
liver 
brain 
liver, heart 
liver, kidney, intestines, adrenal gland, brain, 
mammary gland, ovary 
liver 
liver, heart 
liver, brain, heart 
liver, lung, brain, endothelium, heart, bone marrow 
lung 
liver, GIT, kidney, lung, brain, endothelium, 
placenta, lymphocytes 
fetus, placenta, liver 
kidney 
lung, placenta 
kidney 
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Depending on their metabolic status, humans are divided into poor 
metaboliser (PM), an intermediate metaboliser (IM), an extensive metaboliser (EM) 
or an ultra-rapid (ultra-extensive) metaboliser (UM). The poor metabolisers and 
intermediate metabolisers express dysfunctional or inactive enzymes. They 
possess the homozygous autosomal recessive allele (usually mutant alleles) 
(lngelman-Sundberg & Evans, 2001 ). Extensive metabolisers have enzymes with 
normal activity. They have the heterozygous or homozygous dominant allele. At 
the extreme of the EM phenotype, gene amplification gives rise to the so-called 
ultra-rapid metabolisers. These individuals carry replicate functional copies of the 
genes (lngelman-Sundberg & Evans, 2001 ). 
The most common types of polymorphisms are "single nucleotide 
polymorphisms", known as SNPs. Polymorphisms may be present in introns or 
exons. When they are present in exons, they may result in an amino acid change 
or no change at all. When they are present in introns, they may still regulate gene 
expression (splicing) (Aithal eta/., 1999). 
Pharmacogenetics is best defined as the study of genetic variations that 
cause variation in drug response and includes the genetic polymorphism of drug 
transporter, drug metabolising enzymes and drug receptors (lngelman-Sundberg, 
2001). The aim of pharmacogenetics is to aid physicians in prescribing the 
appropriate dose of the right medicine to a person in an attempt to obtain 
maximum efficacy and minimum toxicity based on genetic tests (Koo & Lee, 2006). 
Individuals who inherit the deficiency in the enzyme may benefit from appropriately 
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adjusted doses of the affected drugs based on genetic tests. Pharmacogenetics is 
a growing discipline with great potential of improving human health-care, in terms 
of understanding individual drug responses, adverse drug reactions associated 
with genetics so that medicine could be tailored accordingly to prevent side effects 
and thus reducing cost of therapy. It becomes more important when the prescribed 
drugs have narrow therapeutic indexes and are metabolised by polymorphic 
enzymes as with repaglinide. 
1.3.3.1 Genetic polymorphisms of CYP2CB 
There are four known human CYP2C enzymes: CYP2C8, CYP2C9, 
CYP2C18 and CYP2C19. These enzymes are responsible for the metabolism of 
about 20% of clinically described drugs (Evans & Reiling, 2004). 
CYP2C8 is the major human hepatic P450, constituting about 12% of total 
microsomal CYP content in the liver (Rendic & Carlo, 1997) in which it conducts 
oxidative metabolism of at least 5% of drugs cleared by phase I metabolism. It can 
also be found in other tissues including the kidney, intestines, adrenal gland, brain, 
mammary gland, ovary and heart as well as in breast cancer tumours (Klose eta/., 
1999, Nishimura eta/., 2003, Knupfer eta/., 2004). 
Drugs for which CYP2C8 contributes significantly to their biotransformation 
include the anticancer drug paclitaxel (Sonnichsen eta/., 1995, Dai eta/., 2001), 
the antidiabetic drug rosiglitazone and troglitazone (Yamazaki et a/., 1999) and 
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repaglinide (Bidstrup et at., 2003), the antimalarial amodiaquine (Dai et a/., 2001) 
and the hydroxymethylglutaryl co-enzyme A reductase inhibitors such as 
cerivastatin and fluvastatin (Muck, 2000, Wang et a/., 2002). Table 1.3 lists 
examples of some substrates, inhibitors and inducers of CYP2C8. 
CYP2C8 is located on chromosome 1 Oq24.1 and consists of nine exons 
(Dai et at., 2001). The CYP2C enzymes are all genetically polymorphic with 20 
SNPs identified thus far (Totah & Rettie, 2005). An updated list of allelic variant is 
available at (www.imm.ki.se/CYPalleles). 
The most common variant alleles are CYP2C8*2 and CYP2C8*3. 
CYP2C8*2 has an lle269Phe substitution in exon 5. CYP2C8*2 is expressed in 
black populations with an allele frequency of 18% but is very rare among white 
subjects (Dai et at., 2001). CYP2C8*3 includes both Arg139Lys and Lys399Arg 
amino acid substitutions in exons 3 and 8 and is expressed most commonly in 
white subjects (allele frequency, 23%). It is quite rare in black subjects (allele 
frequency, 2%) and appears to be absent in Japanese subjects (Dai eta/., 2001). 
CYP2C8*4 represents a mutation that causes an amino acid change lle264Met in 
exon 5 and has a frequency of 8% in white subjects (Bahadur eta/., 2002). The 
CYP2C8*5 variant has a base deletion at position 475 resulting in a frameshift at 
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Table 1.3 Examples of some substrates, inhibitors and inducers of CYP2C8 
Substrates Inhibitors Inducers 
Amodiaquine Gemfibrozil Rifampin 
Cerivastatin Glitazones Phenobarbital 
Montelukast Quercetin 
Paclitaxel Trimethoprim 
Repaglinide 
Rosiglitazone 
Troglitazone 
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